Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTINE THAI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1043224587
CMS profile
1470
Location
HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$693.01

43 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $693.01 43

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $254.16 19
Novartis Pharmaceuticals Corporation $154.92 8
ABBVIE INC. $131.14 9
Organon Llc $35.89 2
UCB, Inc. $35.61 2
E.R. Squibb & Sons, L.L.C. $35.54 1
Boehringer Ingelheim Pharmaceuticals, Inc. $25.29 1
PFIZER INC. $20.46 1

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTINE THAI

NPI 1043224587 · CMS profile ID 1470

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043224587?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043224587?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043224587?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–43 of 43 matching records. This page contains 43 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1043224587?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

43 matching records · $693.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 43 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–43 of 43.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $16.5612/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213378 CMS
Amgen Inc. $11.9412/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723903 CMS
Organon Llc $22.9612/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136296343 CMS
PFIZER INC. $20.4612/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131155743 CMS
Novartis Pharmaceuticals Corporation $17.6711/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087396456 CMS
Amgen Inc. $15.5011/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723901 CMS
ABBVIE INC. $29.0911/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213376 CMS
Novartis Pharmaceuticals Corporation $17.0810/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087396454 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.2910/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117848005 CMS
Organon Llc $12.9309/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136296341 CMS
Amgen Inc. $13.6809/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723899 CMS
Novartis Pharmaceuticals Corporation $15.1209/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087396450 CMS
Amgen Inc. $16.6609/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723883 CMS
ABBVIE INC. $19.7709/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213374 CMS
Amgen Inc. $14.9609/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723897 CMS
Amgen Inc. $13.9308/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723919 CMS
Amgen Inc. $8.0308/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723895 CMS
Novartis Pharmaceuticals Corporation $18.5808/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087396448 CMS
UCB, Inc. $18.6408/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143303654 CMS
Amgen Inc. $10.9407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723917 CMS
ABBVIE INC. $9.9706/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213372 CMS
E.R. Squibb & Sons, L.L.C. $35.5406/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101317810 CMS
Amgen Inc. $8.1706/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723893 CMS
Amgen Inc. $14.7906/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723915 CMS
UCB, Inc. $16.9705/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143303649 CMS
ABBVIE INC. $7.5305/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213370 CMS
Novartis Pharmaceuticals Corporation $23.4305/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087396442 CMS
Amgen Inc. $8.9404/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723913 CMS
Novartis Pharmaceuticals Corporation $18.8204/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087396430 CMS
Amgen Inc. $9.7604/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723911 CMS
Amgen Inc. $23.2003/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723909 CMS
Amgen Inc. $20.7703/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723891 CMS
Amgen Inc. $15.1703/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723907 CMS
ABBVIE INC. $10.0903/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213368 CMS
Novartis Pharmaceuticals Corporation $23.2503/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087396428 CMS
ABBVIE INC. $17.0603/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213366 CMS
Amgen Inc. $6.8703/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723905 CMS
Amgen Inc. $26.3502/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723889 CMS
Amgen Inc. $8.4302/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723887 CMS
ABBVIE INC. $16.7102/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213364 CMS
Novartis Pharmaceuticals Corporation $20.9701/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087396426 CMS
ABBVIE INC. $4.3601/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106213362 CMS
Amgen Inc. $6.0701/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111723885 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,357.35 137
PY2020 $1,472.25 78
PY2021 $298.93 19
PY2022 $874.35 56
PY2023 $974.73 69
PY2024 $693.01 43
PY2025 $811.99 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,372,053.89 61
PY2024 Recipient $8,444.46 4
PY2024 Principal investigator $1,430,507.12 79
PY2023 Recipient $8,498.49 1
PY2023 Principal investigator $1,858,436.22 86
PY2022 Recipient $72,841.00 2
PY2022 Principal investigator $1,860,641.35 160
PY2021 Recipient $2,012.04 2
PY2021 Principal investigator $577,779.35 91
PY2020 Recipient $2,580.07 2
PY2020 Principal investigator $908,629.40 110
PY2019 Recipient $16,824.73 4
PY2019 Principal investigator $518,505.93 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $791.39 12/31/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH HUNTINGTON BEACH
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998414133
Principal investigator 1 Janssen Research & Development, LLC $1,050.00 12/15/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 986144609
Principal investigator 1 Janssen Research & Development, LLC $4,844.00 12/15/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 986144611
Principal investigator 1 ABBVIE INC. $8,464.00 12/07/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohns Disease. No dispute reported 06/30/2026 998411205
Principal investigator 1 ABBVIE INC. $250.00 11/16/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998408275
Principal investigator 1 ABBVIE INC. $250.00 11/16/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998408277
Principal investigator 1 ABBVIE INC. $337.92 11/07/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998406313
Principal investigator 1 ABBVIE INC. $2,438.16 11/07/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998406315
Principal investigator 1 Janssen Research & Development, LLC $5,099.00 11/02/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 986144607
Principal investigator 1 ABBVIE INC. $150.00 10/17/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998404353
Principal investigator 1 ABBVIE INC. $500.00 10/12/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998403975
Principal investigator 1 Janssen Research & Development, LLC $4,992.00 09/29/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 986144603
Principal investigator 1 ABBVIE INC. $5,655.00 09/21/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998400269
Principal investigator 1 ABBVIE INC. $100.00 09/21/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998400271
Principal investigator 1 ABBVIE INC. $43.20 09/15/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) No dispute reported 06/30/2026 998399971
Principal investigator 1 ABBVIE INC. $3,111.68 09/13/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998399211
Principal investigator 1 ABBVIE INC. $5,611.60 09/13/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998399213
Principal investigator 1 ABBVIE INC. $2,438.16 09/05/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998397601
Principal investigator 1 Janssen Research & Development, LLC $133.00 08/24/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 986144601
Principal investigator 1 ABBVIE INC. $517.12 08/15/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998395481
Principal investigator 1 ABBVIE INC. $4,297.80 08/15/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998395483
Principal investigator 1 ABBVIE INC. $1,272.00 08/15/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998395485
Principal investigator 1 ABBVIE INC. $172.80 08/10/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 998394725
Principal investigator 1 ABBVIE INC. $4,361.04 08/03/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998393317
Principal investigator 1 Janssen Research & Development, LLC $1,264.00 07/31/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 986144599
Principal investigator 1 Janssen Research & Development, LLC $12,482.00 07/28/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 986144597
Principal investigator 1 ABBVIE INC. $150.00 07/13/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998391433
Principal investigator 1 ABBVIE INC. $2,166.40 07/12/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998390665
Principal investigator 1 ABBVIE INC. $4,160.00 07/11/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998390337
Principal investigator 1 Eli Lilly and Company $7,821.45 07/11/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038074151
Principal investigator 1 ABBVIE INC. $2,188.56 07/06/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998389747
Principal investigator 1 ABBVIE INC. $1,307.50 06/15/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 998386991
Principal investigator 1 ABBVIE INC. $3,542.40 06/08/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998385845
Principal investigator 1 ABBVIE INC. $2,288.38 06/08/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998385911
Principal investigator 1 ABBVIE INC. $16,885.70 06/08/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998385913
Principal investigator 1 Janssen Research & Development, LLC $4,360.00 06/01/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 986144591
Principal investigator 1 Janssen Research & Development, LLC $10,235.00 06/01/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 986144593
Principal investigator 1 Janssen Research & Development, LLC $3,473.00 05/15/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 986144587
Principal investigator 1 ABBVIE INC. $85.00 05/11/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 998383015
Principal investigator 1 ABBVIE INC. $1,387.16 05/11/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 998383017
Principal investigator 1 ABBVIE INC. $9,835.80 05/11/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998383019
Principal investigator 1 ABBVIE INC. $4,085.28 05/04/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998380703
Principal investigator 1 ABBVIE INC. $7,292.90 05/03/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998380353
Principal investigator 1 Janssen Research & Development, LLC $14,959.00 05/01/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 986144589
Principal investigator 1 ABBVIE INC. $200.00 04/18/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998378883
Principal investigator 1 ABBVIE INC. $3,312.90 04/13/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998378493
Principal investigator 1 ABBVIE INC. $24,469.90 04/13/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998378661
Principal investigator 1 ABBVIE INC. $3,010.10 04/13/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 998378721
Principal investigator 1 Eli Lilly and Company $217.05 04/10/2023 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A RANDOMIZED ACTIVE-CONTROLLED PARALLEL-GROUP PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1038102701
Principal investigator 1 Eli Lilly and Company $76,355.00 04/04/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1038140855
Principal investigator 1 ABBVIE INC. $2,857.98 03/16/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998374043
Principal investigator 1 ABBVIE INC. $3,656.24 03/16/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998374079
Principal investigator 1 ABBVIE INC. $13,245.30 03/16/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998374099
Principal investigator 1 ABBVIE INC. $17,399.20 03/16/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998374207
Principal investigator 1 ABBVIE INC. $4,489.18 03/16/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 998374269
Principal investigator 1 ABBVIE INC. $50.00 03/09/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998372875
Principal investigator 1 Janssen Research & Development, LLC $5,650.00 03/07/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 986144583
Principal investigator 1 Janssen Research & Development, LLC $1,264.00 02/27/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 986144579
Principal investigator 1 Eli Lilly and Company $6,423.43 02/23/2023 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1038109159
Principal investigator 1 ABBVIE INC. $1,880.82 02/16/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 998370957
Principal investigator 1 ABBVIE INC. $3,206.68 02/16/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 998371397
Principal investigator 1 ABBVIE INC. $3,111.68 02/09/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998369287
Principal investigator 1 ABBVIE INC. $15,011.10 02/09/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998370295
Principal investigator 1 ABBVIE INC. $3,262.90 02/09/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998370297
Recipient Eli Lilly and Company $8,498.49 02/08/2023 Covered Recipient Physician A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038048969
Principal investigator 1 ABBVIE INC. $2,206.48 02/07/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998368849
Principal investigator 1 Janssen Research & Development, LLC $5,878.00 02/03/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 986144585
Principal investigator 1 Eli Lilly and Company $4,660.00 01/30/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 1038125069
Principal investigator 1 Janssen Research & Development, LLC $2,026.00 01/30/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 986144581
Principal investigator 1 Eli Lilly and Company $627.54 01/26/2023 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A PHASE 3 MULTICENTER OPEN LABEL LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1038105113
Principal investigator 1 Eli Lilly and Company $1,645.61 01/26/2023 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP TWO-ARM PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038109147
Principal investigator 1 Eli Lilly and Company $625.20 01/26/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038125181
Principal investigator 1 ABBVIE INC. $500.00 01/25/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998367251
Principal investigator 1 Eli Lilly and Company $11,142.00 01/25/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1038119085
Principal investigator 1 Eli Lilly and Company $1,023.76 01/19/2023 Non-covered Recipient Entity
VANCOUVER CLINIC INC PS
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038148881
Principal investigator 1 ABBVIE INC. $2,557.18 01/12/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998365595
Principal investigator 1 ABBVIE INC. $16,857.10 01/12/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998365597
Principal investigator 1 ABBVIE INC. $7,882.30 01/12/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 998365599
Principal investigator 1 ABBVIE INC. $50.00 01/12/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 998365617
Principal investigator 1 Eli Lilly and Company $1,281.79 01/11/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1038119073
Principal investigator 1 Eli Lilly and Company $14,916.00 01/10/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3 MULTICENTER OPEN LABEL LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1038117479
Principal investigator 1 Eli Lilly and Company $15,936.00 01/10/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED ACTIVE-CONTROLLED PARALLEL-GROUP PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1038125081
Principal investigator 1 ABBVIE INC. $2,084.40 01/05/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 998363939
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $77,971.00 01/05/2023 Non-covered Recipient Entity
Christine Thai Md
Phase II Study SLE - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1027447235
Principal investigator 1 Eli Lilly and Company $1,262,177.00 01/03/2023 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038074097
Principal investigator 1 Eli Lilly and Company $7,406.00 01/03/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038116023
Principal investigator 1 Eli Lilly and Company $63,060.00 01/03/2023 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP TWO-ARM PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1038125191